Hansa Biopharma AB

Hansa Medical Interim report April – June 2016

Thu, Jul 21, 2016 08:30 CET

Continued positive development of IdeS in clinical studiesSecond quarter in brief Business highlights›› US Food and Drug Administration (FDA) cleared Hansa Medical’s IND application for a study with IdeS in kidney transplantation ›› All patients are recruited and successfully desensitized in Swedish Phase II study with IdeS in kidney transplantation ›› Successful desensitization with IdeS in all recruited patients in ongoing US Phase II study with kidney transplantation ›› Hansa Medical appointed Henk Doude van Troostwijk as Vice President, Commercial Operations ›› Annual

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

Fri, Nov 13, 2015 08:45 CET

At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles, will show data from one of his ongoing studies where highly sensitized patients are desensitized and treated with Hansa Medical’s lead candidate drug IdeS prior to transplantation.Data will be shown from a patient with a PRA level of 100% who was treated and transplanted successfully in July this year. The investigator-sponsored clinical phase II study, which was initiated and led by Dr. Jordan, is an open-

Contacts

Hansa Medical Interim report April – June 2016

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

Subscribe

Media

Share

Contacts

Hansa Medical Interim report April – June 2016

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

Subscribe

Media